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Introduction
Since the emergence of the novel coronavirus, severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), in Wuhan, China in 2019 [1], the resulting coronavirus disease 2019 (COVID-19) disease
has rapidly transitioned into a global pandemic with over 31000 deaths and 215000 infections in the UK
as of 10 May 2020 [2]. Confirmation of SARS-CoV-2 infection requires reverse transcriptase PCR
(RT-PCR) testing [3]. Chest radiographic and/or computed tomography (CT) imaging is also central to
diagnosis and management [4].
The scale of the COVID-19 pandemic has resulted in the acquisition of huge volumes of imaging data.
Traditionally, research using imaging data constituted collation of data within single hospitals or groups
of hospitals at most. Endeavours on a local scale have the constraint that not all patient subgroups or
disease manifestations might be captured in the collected data. It has long been recognised that there
is an acute need to curate larger, more comprehensive datasets to better understand a disease.
COVID-19 has arrived in an era where advances in computational power, aligned with an increased
availability of big data and the development of self-learning neural networks, have begun to redefine
research in medicine. In recent years, computer algorithms trained on imaging data, widely available
on the internet, have been adapted to the task of medical image analysis [5, 6]. For computer
algorithms to be successfully applied to medical image analysis, it is imperative that they train on large
volumes and representative examples of imaging data. These are typically orders of magnitude larger
than traditional imaging research datasets, and beyond the capacity of traditional research
e-infrastructure.
The National Health Service (NHS) in the UK has long sought national repositories of linked clinical and
imaging data, which are essential for applications of artificial intelligence (AI) computing systems in
healthcare. Historically, logistical barriers to this have seemed insurmountable and progress has been
notoriously slow. Yet, one aspect of the COVID-19 response has been the issue of a notice under
Regulation 3(4) of the Health Service Control of Patient Information Regulations 2002 in the UK, which
has temporarily eased data sharing restrictions to facilitate COVID-19-specific public health research and
scientific collaboration over the course of the emergency.
The British Society of Thoracic Imaging research network began a multicentred COVID-19 imaging study
[7], which grew into a partnership with NHSX to create the National COVID-19 Chest Imaging Database
(NCCID; https://nhsx.github.io/covid-chest-imaging-database). NCCID has put in place mechanisms to
collate all chest imaging and pre-specified clinical data from every UK hospital where patients undergo a
RT-PCR test for COVID-19. This will include all RT-PCR-positive patients and a representative sample of
RT-PCR-negative patients. The study aims to identify information in COVID-19 imaging that may be
inconspicuous to the human eye, but which is extractable by computer algorithms. Such buried
information may allow the early identification of patients at risk of deterioration, thereby anticipating
future intensive care needs. AI algorithms may also demonstrate how comprehensive characterisation of
COVID-19 may improve care/outcomes.
NCCID data and image transfer solutions are robust and secure, including those adapted from techniques
tried and tested on numerous research studies involving large-scale medical image collection [8].
To maximise efficient resource utilisation in busy hospitals during the course of the pandemic, we are
linking our imaging data to the International Severe Acute Respiratory and Emerging Infection
Consortium (ISARIC) UK Clinical Characterisation Protocol (https://isaric.tghn.org/UK-CCP), and aim to
link to the Intensive Care National Audit and Research Centre (ICNARC; www.icnarc.org). ISARIC
investigators are collating clinical information and biological samples for COVID-19 cases of all ages
admitted to hospitals, while ICNARC collates detailed data from adults in the intensive care setting. The
study has also been supported by Health Data Research UK as part of its UK response to COVID-19.
An endeavour of this scale, rarely attempted before in the NHS, can only succeed if the radiology and
scientific community contribute their time, effort and available data. ISARIC has open source processes
and already has established data and material sharing from UK COVID-19 cases [9]. The NCCID
initiative will create an open, well-governed database for researchers from academia and industry to add to
COVID-19 knowledge collectively. Public, patient and professional trust is vital to NCCID and COVID-19
in general, and we consider accessibility and feedback on data uses as central to good governance. The
NCCID data access committee aim to link to researchers who are asking related scientific questions, using
complementary methodologies. NCCID will also set aside a portion of its data to enable validation of AI
models. This will maintain the highest standards of governance throughout the emergency and allow
technology developers to validate their algorithms promptly.
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NCCID data
Imaging data
Chest radiographs
The UK prioritised the use of chest radiographs in the clinical work-up of patients suspected of
COVID-19 [10]. The choice of chest radiographs as the primary diagnostic imaging test was pragmatic,
given the reported limited sensitivity of CT imaging in COVID-19 diagnosis [11]. The choice also reflected
concerns regarding seeding of infection via CT scanners contaminated with virus particles, as well as the
limited numbers of CT scanners serving the UK population when compared with other European
countries [12]. Accordingly, a large proportion of imaging in NCCID will consist of chest radiographs
acquired at initial presentation of the patient to hospital and throughout the patient’s hospital stay
(figure 1). NCCID will collect chest radiographs from all RT-PCR-positive COVID-19 patients in hospitals
throughout the UK. In addition, a number of chest radiographs from RT-PCR-negative patients will be
collected from sites as a representative control population.
CT chest imaging
NCCID will collect all chest CT imaging in RT-PCR-positive COVID-19 patients. This will include
non-contrast-enhanced chest CT imaging, CT pulmonary angiograms and CT coronary angiograms.
Previous chest imaging
For all RT-PCR-positive COVID-19 patients, NCCID will acquire all chest imaging performed in the
previous 3 years. For RT-PCR-negative patients, NCCID will acquire any chest imaging performed in the
previous 4 weeks.
Clinical data
Clinical data collected from RT-PCR-positive COVID-19 patients will include demographic information,
patient comorbidity, smoking and medication histories, clinical observations, admission blood test results,
a) b) c)
d) e) f)
FIGURE 1 Imaging from a 61-year-old man presenting with a 7-day history of feeling unwell and increasing breathlessness. a) The chest
radiograph on admission demonstrated patchy peripheral consolidation in the middle and lower zones. Axial CT images of the b) upper and
c) lower lung zones on day 6 of admission confirmed multifocal peripheral consolidation, in keeping with the diagnosis of COVID-19. d) A repeat
chest radiograph taken 3.5 weeks later showed marked resolution of the consolidation, confirmed on repeat CT imaging of e) upper and f) lower
lung zones, although a degree of architectural distortion was then evident within the lungs. Artificial intelligence tools, when applied to imaging
and corresponding clinical data at scale, can allow the quantitation of patterns of disease progression in COVID-19. Unsupervised deep learning
methods could help identify discrete COVID-19 patient phenotypes that manifest differing disease courses. Image analysis may also allow
prediction of those patients that are likely to manifest chronic multisystem sequelae following their acute infection, which may inform future
resource prioritisation in healthcare systems.
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and outcomes including time of intensive care unit admission and survival. The imaging will link to other
clinical databases such as ISARIC to allow analyses against more detailed clinical information.
Data access
We anticipate that, in May 2020, NCCID data will be released to interested academic and commercial
groups. Given that NCCID will be of particular interest to AI researchers, a portion of the data will be
segregated to allow rigorous and independent validation of AI models. Data access will be initiated
through online applications, to be filled in and submitted according to the instructions on the NCCID
website. Applications will then be assessed by a central data access committee comprising scientific
advisors, technology advisors, information-governance advisors, patient/ethics advisors and system
advisors, to evaluate the positive impact on the NHS overall. Successful applicants can access the data on a
cloud-based Amazon S3 bucket, and transfer it onto their computing infrastructure, which are required to
fulfil high standards of IT security.
Discussion
In these challenging times, research efforts necessary to better understand COVID-19 cannot afford to be
fragmented and uncoordinated. Accelerating insights and discovery necessitates leveraging economies of
scale and resource amongst researchers, institutions and companies. We believe NCCID will quickly
improve COVID-19 understanding and patient care and build on early insights into COVID-19 [13–15].
The scale of the current pandemic requires the best minds, data, algorithms and research programmes to
come together quickly. We are fortunate in the UK to have an abundance of internationally recognised
researchers working on COVID-19. We hope that NCCID provides a common UK resource to fuel
international efforts in tackling COVID-19 and allows better preparedness for similar future needs.
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